Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$141.97
+1.9%
$135.47
$119.59
$145.62
$15.77B0.88789,253 shs2.24 million shs
Exact Sciences Co. stock logo
EXAS
Exact Sciences
$45.45
+0.4%
$60.61
$43.59
$100.77
$8.39B1.263.79 million shs2.14 million shs
PPD, Inc. stock logo
PPD
PPD
$47.28
$47.27
$31.54
$47.41
$16.61B1.961.91 million shsN/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$165.21
$167.50
$93.00
$175.95
$10.70B1.31837,472 shs57 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.00%+0.49%+4.13%+13.87%+7.02%
Exact Sciences Co. stock logo
EXAS
Exact Sciences
0.00%-8.81%-24.93%-23.54%-44.29%
PPD, Inc. stock logo
PPD
PPD
0.00%0.00%0.00%0.00%0.00%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
4.8827 of 5 stars
2.14.04.24.72.82.52.5
Exact Sciences Co. stock logo
EXAS
Exact Sciences
4.4758 of 5 stars
3.54.00.04.72.72.50.6
PPD, Inc. stock logo
PPD
PPD
N/AN/AN/AN/AN/AN/AN/AN/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
2.25
Hold$146.673.31% Upside
Exact Sciences Co. stock logo
EXAS
Exact Sciences
2.92
Moderate Buy$95.40109.90% Upside
PPD, Inc. stock logo
PPD
PPD
N/AN/AN/AN/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
N/AN/AN/AN/A

Current Analyst Ratings

Latest EXAS, DGX, PPD, and PRAH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/30/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$152.00 ➝ $155.00
5/9/2024
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$90.00 ➝ $85.00
5/9/2024
Exact Sciences Co. stock logo
EXAS
Exact Sciences
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$85.00 ➝ $80.00
5/9/2024
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$100.00 ➝ $80.00
4/25/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$138.00 ➝ $144.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$135.00 ➝ $145.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$139.00 ➝ $146.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$145.00 ➝ $150.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$150.00 ➝ $155.00
4/3/2024
Exact Sciences Co. stock logo
EXAS
Exact Sciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00
3/20/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$145.00
(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$9.25B1.70$12.74 per share11.14$58.23 per share2.44
Exact Sciences Co. stock logo
EXAS
Exact Sciences
$2.50B3.36$0.02 per share2,668.66$16.98 per share2.68
PPD, Inc. stock logo
PPD
PPD
$4.68B3.55$1.99 per share23.71($1.21) per share-39.07
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$3.18B3.36$6.09 per share27.11$23.06 per share7.16

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$854M$7.4319.1115.043.089.11%15.52%7.23%7/24/2024 (Estimated)
Exact Sciences Co. stock logo
EXAS
Exact Sciences
-$204.15M-$1.32N/AN/AN/A-9.48%-7.12%-3.46%8/6/2024 (Estimated)
PPD, Inc. stock logo
PPD
PPD
$153.69M$1.0047.2825.982.116.11%-89.48%7.94%N/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$197.04M$3.9050.5226.31N/A6.40%20.49%7.07%N/A

Latest EXAS, DGX, PPD, and PRAH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024Q1 2024
Exact Sciences Co. stock logo
EXAS
Exact Sciences
-$0.50-$0.50N/A-$0.40$624.95 million$637.52 million
4/23/2024Q1 2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$1.86$2.04+$0.18$2.36$2.29 billion$2.37 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$2.842.00%+8.08%38.22%13 Years
Exact Sciences Co. stock logo
EXAS
Exact Sciences
N/AN/AN/AN/AN/A
PPD, Inc. stock logo
PPD
PPD
N/AN/AN/AN/AN/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
N/AN/AN/AN/AN/A

Latest EXAS, DGX, PPD, and PRAH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/15/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
quarterly$0.752.13%7/8/20247/8/20247/22/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.59
0.97
0.89
Exact Sciences Co. stock logo
EXAS
Exact Sciences
0.66
1.64
1.45
PPD, Inc. stock logo
PPD
PPD
N/A
1.23
1.23
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.74
1.21
1.21

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
88.06%
Exact Sciences Co. stock logo
EXAS
Exact Sciences
88.82%
PPD, Inc. stock logo
PPD
PPD
87.82%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
93.93%

Insider Ownership

CompanyInsider Ownership
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.79%
Exact Sciences Co. stock logo
EXAS
Exact Sciences
1.36%
PPD, Inc. stock logo
PPD
PPD
1.90%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
1.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
48,000111.09 million110.21 millionOptionable
Exact Sciences Co. stock logo
EXAS
Exact Sciences
6,600184.53 million182.02 millionOptionable
PPD, Inc. stock logo
PPD
PPD
26,000351.40 million344.72 millionNot Optionable
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
18,10064.80 millionN/AOptionable

EXAS, DGX, PPD, and PRAH Headlines

Recent News About These Companies

PRA Health Sciences
College of Health Sciences & Professions
Accelerating Discovery
PRAH Historical Data
Western University of Health Sciences
Master Of Public Health
Health Sciences Transfer Policies
Interprofessional Education
Mercy College of Health Sciences
Independent/Supplementary Prescribing
Public Health Doctoral Program
Health Sciences Programs
UK insurers need to up their game on cyber gaps, says PRA
PRA forms the First Ternate Cavite Rowing Academy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Quest Diagnostics logo

Quest Diagnostics

NYSE:DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Exact Sciences logo

Exact Sciences

NASDAQ:EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
PPD logo

PPD

NASDAQ:PPD
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
PRA Health Sciences logo

PRA Health Sciences

NASDAQ:PRAH
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.